<DOC>
	<DOCNO>NCT01696058</DOCNO>
	<brief_summary>The overall objective study assess efficacy safety 12 week , daily , orally inhale co-administration olodaterol 5 µg ( deliver Respimat® Inhaler ) tiotropium ( deliver Handihaler® Spiriva Handihaler® ) , compare tiotropium ( Spiriva Handihaler® ) monotherapy lung function patient COPD .</brief_summary>
	<brief_title>Co-administration Olodaterol Respimat® Tiotropium Handihaler®</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent International Conference HarmonizationGood Clinical Practice ( ICHGCP ) guideline prior participation trial , include medication washout restriction . 2 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator FEV1 ≥ 30 % &lt; 80 % predict normal postbronchodilator FEV1/FVC &lt; 70 % Visit 1 . 3 . Male female patient , 40 year age old . 4 . Patients must current exsmokers smoke history 10 pack year 5 . Patients must able : perform technically acceptable pulmonary function test , maintain record ( paper diary ) . 6 . Patients must able inhale medication competent manner Respimat Inhaler well Handihaler . Exclusion criterion : 1 . Patients significant disease COPD ; significant disease define disease , opinion investigator , may ( ) put patient risk participation study , ( ii ) influence result study , ( iii ) cause concern regard patient ability participate study . 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis ; patient AST &gt; x2 ULN , ALT &gt; x2 ULN , bilirubin &gt; x2 ULN creatinine &gt; x2 ULN exclude regardless clinical condition ( repeat laboratory evaluation conduct patient ) . 3 . Patients history asthma . For patient allergic rhinitis atopy , source documentation require verify patient asthma . If patient total blood eosinophil count ≥600/mm3 , source documentation require verify increase eosinophil count relate nonasthmatic condition . 4 . A diagnosis thyrotoxicosis ( due know class side effect profile ß2agonists ) . 5 . A diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) ( due know class side effect profile ß2agonists ) . 6 . A history myocardial infarction within 1 year screen visit ( Visit 1 ) . 7 . Unstable lifethreatening cardiac arrhythmia . 8 . Hospitalization heart failure within past year . 9 . Known active tuberculosis . 10 . A malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) . 11 . A history lifethreatening pulmonary obstruction . 12 . A history cystic fibrosis . 13 . Clinically evident bronchiectasis . 14 . A history significant alcohol drug abuse . 15 . Patients undergone thoracotomy pulmonary resection ( patient history thoracotomy reason evaluate per exclusion criterion No . 1 ) . 16 . Patients treat oral patch ßadrenergics . 17 . Patients treat oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 18 . Patients regularly use daytime oxygen therapy one hour per day investigator opinion unable abstain use oxygen therapy clinic visit . 19 . Patients complete pulmonary rehabilitation program six week prior screen visit ( Visit 1 ) patient currently pulmonary rehabilitation program . 20 . Patients take investigational drug within one month six half life ( whichever great ) prior screen visit ( Visit 1 ) . 21 . Patients know hypersensitivity ßadrenergic drug , BAC , EDTA , component Respimat® inhalation solution . 22 . Patients know hypersensitivity anticholinergic drug , lactose , component HandiHaler® . 23 . Pregnant nursing woman . 24 . Women childbearing potential use highly effective method birth control* . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation , postmenopausal least two year . * per ICH M3 ( R2 ) highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) . 25 . Patients previously randomise study currently participate another study . 26 . Patients unable comply pulmonary medication restriction prior randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>